Epilepsy-focused cell therapy biotech lands $120 million for potential ‘game-changer’

The one-time treatment could be transformative to patients with the most common form of focal epilepsy and, potentially, in Alzheimer’s disease and other nervous system disorders.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Advertisement — Advertise with Biotech Networks